In Reply: Impact of Respiratory Syncytial Virus Prevention in Infancy on Prevalence of Asthma Among Native American Children

To the Editors: We have reviewed the article titled “Impact of RSV Prevention in Infancy on Prevalence of Asthma Among 9 to 14-year-old Native American Children in the Southwest United States” by Hartman et al1 with great interest. This study provides valuable insight into the potential long-term effects of respiratory syncytial virus (RSV) prevention on childhood asthma prevalence in native American Children. While the authors’ work contributes significantly to the understanding of RSV’s role in asthma development, we would like to highlight several points for further consideration and potential improvement. Firstly, although the study carefully documents the respiratory health of children who were part of the motavizumab clinical trial, it falls short in addressing the clinical significance of the differences observed. The study reports a lower point prevalence of asthma in motavizumab recipients compared to placebo, but the differences are not statistically significant. The authors attribute this to insufficient statistical power due to the sample size. While this is a reasonable explanation, it underscores a major limitation of the study. Further research should prioritize larger cohort sizes and more robust statistical methods to achieve more definitive conclusions on the long-term impacts of RSV prevention on asthma outcomes.1 Additionally, the study design, while valuable, does not account for potential confounding factors that could influence asthma prevalence. The study population consisted solely of Native American children, a group known to have higher asthma rates compared to other ethnic groups. Although this focus allows for an in-depth analysis within this specific demographic, the findings may not be generalizable to a broader population. Including children from different ethnic backgrounds could provide more comprehensive insights into the universal applicability of RSV prevention for asthma mitigation.2 The lack of long-term follow-up beyond the age of 14 also limits the clinical relevance of the findings. Asthma often evolves over time, and symptoms may appear or worsen in later adolescence and adulthood. The study would have benefited from a more extended follow-up period to better capture the progression of asthma and evaluate the sustained effects of RSV prevention interventions.3 Finally, while the study makes valuable strides in linking early RSV prevention with a reduction in asthma-related outcomes, the relationship between RSV prevention and the overall quality of life, including functional limitations in affected children, remains unexplored. Further investigations should integrate standardized outcome measures, Such as the Pediatric Asthma Quality of Life Questionnaire, to better understand the full impact of RSV prevention on asthma symptoms and good quality of life in this population.4 In conclusion, Hartman et al.’s study provides promising data on RSV prevention’s potential to reduce asthma prevalence in Native American children, yet further research with larger sample sizes, longer follow-up periods, and a diverse population is needed to solidify these findings. The ongoing evaluation of RSV prevention strategies is crucial, especially for high-risk communities, and should continue to address the multifactorial aspects of asthma development and management. ACKNOWLEDGMENTS We are thankful to Dr Salman Zahir for guiding us during our writing of this Editorial.